

## 'Multicopy Multivalent' Glycopolymer-Stabilized Gold Nanoparticles as Potential Synthetic Cancer Vaccines

Alison L. Parry,<sup>†,§</sup> Natasha A. Clemson,<sup>†</sup> James Ellis,<sup>†</sup> Stefan S. R. Bernhard,<sup>†</sup> Benjamin G. Davis,<sup>\*,§</sup> and Neil R. Cameron<sup>\*,†</sup>

<sup>†</sup>Department of Chemistry and Biophysical Sciences Institute, Durham University, South Road, Durham, DH1 3LE, U.K.


<sup>§</sup>Department of Chemistry, University of Oxford, Chemistry Research Laboratory, 12 Mansfield Road, Oxford, OX1 3TA, U.K.

### S Supporting Information

**ABSTRACT:** Mucin-related carbohydrates are overexpressed on the surface of cancer cells, providing a disease-specific target for cancer immunotherapy. Here, we describe the design and construction of peptide-free multivalent glycosylated nanoscale constructs as potential synthetic cancer vaccines that generate significant titers of antibodies selective for aberrant mucin glycans. A polymerizable version of the Tn-antigen glycan was prepared and converted into well-defined glycopolymers by Reversible Addition–Fragmentation chain Transfer (RAFT) polymerization. The polymers were then conjugated to gold nanoparticles, yielding 'multicopy-multivalent' nanoscale glycoconjugates. Immunological studies indicated that these nanomaterials generated strong and long-lasting production of antibodies that are selective to the Tn-antigen glycan and cross-reactive toward mucin proteins displaying Tn. The results demonstrate proof-of-concept of a simple and modular approach toward synthetic anticancer vaccines based on multivalent glycosylated nanomaterials without the need for a typical vaccine protein component.

Healthy cells of the mammary gland are characterized by the surface presentation of branched, O-linked core 2 glycans containing high levels of *N*-acetyl-D-glucosamine (GlcNAc). However, proteins on the surface of breast cancer cells instead present mainly linear, truncated core 1 mucin-type glycans such as  $\alpha$ -*N*-acetyl-D-galactosamine ( $\alpha$ GalNAc, the Tn-antigen glycan) (Figure 1), with complete or near-complete absence of core 2 residues.<sup>1</sup> These differences have been targeted as a strategy for cancer immunotherapy.<sup>2</sup> Accordingly, multivalent glycoconjugates have been prepared in which mucin glycans are presented on a variety of scaffolds, including peptides,<sup>3</sup> lipopeptides,<sup>4</sup> dendrimers<sup>5</sup> and proteins.<sup>6</sup> Some of these approaches have developed as far as clinical trials.<sup>7</sup>

Nanomaterials represent an alternative platform for the presentation of glycans<sup>8</sup> that allow greater synthetic control and higher density than on current protein scaffolds. Carbohydrate-presenting gold nanoparticles (AuNPs)<sup>9</sup> decorated with small molecule thiolated glycans have been used as tools to study carbohydrate–carbohydrate interactions,<sup>10</sup> in antiadhesive therapy,<sup>11</sup> and as anti-HIV<sup>12</sup> and cancer vaccine candidates.<sup>13</sup> However, these typically monomolecular sugar coatings do not represent well the structure of mucin glycoproteins, which



**Figure 1.** Overview of approach to develop gold nanoparticle-based synthetic anticancer vaccines. Breast cancer cells express aberrant mucins displaying Core 1 glycans such as the Tn-antigen glycan. This 'multicopy-multivalent' presentation is mimicked by displaying Tn-antigen glycan glycopolymers on the surface of nanoparticles.


feature a dense presentation of glycans attached to a protein backbone. We hypothesized that presenting core 1 glycans such as  $\alpha$ GalNAc in a 'multicopy-multivalent' manner<sup>14</sup> might produce a nanoparticle with a surface that mimics much more closely the surface of cancer cells which engage the surface receptors of cells of the immune system, and thus produce an effective synthetic vaccine (Figure 1).

Novel Tn glycan monomer **2** was synthesized using a nonparticipatory glycosyl donor sugar reactant to create the desired  $\alpha$ -anomeric stereochemistry (Figure 2).<sup>15</sup>  $\alpha$ -Glycosylation of the linker moiety with glycosyl donor **1** in diethyl ether/DCM gave the azido-glycoside in 87%. Following successful attachment of the sugar precursor, the azide functionality was converted to acetamide using a one-pot Staudinger reduction<sup>16</sup>-acetylation procedure. The unwanted  $\beta$ -anomer was readily removed to give linked pure  $\alpha$ -glycoside. Selective methanolysis followed by careful neutralization allowed removal of the acetate protecting groups to yield the pure Tn  $\alpha$ -anomer **2**. In this way, gram quantities of the polymerizable antigen building block were readily generated.

Controlled glycopolymers were prepared by Reversible Addition–Fragmentation chain Transfer (RAFT) polymerization.<sup>17</sup> Polymers of varied length and composition could be prepared (Table 1) by varying feedstock composition, ratios and conditions. First, a Tn-antigen glycan monocomponent homopolymer was created in an optimum yield of 65% in a

Received: May 19, 2013

Published: June 13, 2013



**Figure 2.** Preparation and characterization of Tn-antigen gold nanoparticles (for abbreviations see Supporting Information). Reagents, conditions and yields: (i)  $\text{NaN}_3$ , CAN,  $\text{CH}_3\text{CN}$ ,  $-20^\circ\text{C}$ , 30 h, 80%; (ii) PhSH, DiPEA,  $\text{CH}_3\text{CN}$ , 1 h, 72%; (iii)  $\text{K}_2\text{CO}_3$ ,  $\text{CCl}_3\text{CN}$ , dichloromethane (DCM), 8 h, 62%; (iv) HEMAm, TMSOTf,  $\text{Et}_3\text{N}$ ,  $\text{Et}_2\text{O}/\text{DCM}$  (2:1),  $-20^\circ\text{C}$ , 30 min, 80%; (v) DPPE, DCM, 1 h then  $\text{Ac}_2\text{O}$ , DMAP,  $\text{Et}_3\text{N}$ ,  $\text{H}^+$  resin, 55%  $\alpha$ -anomer; (vi)  $\text{K}_2\text{CO}_3$ , MeOH, 65%; (vii) PEGMA, CPADB, ACVA,  $70^\circ\text{C}$ , 48 h, 51–75%. Insets show representative dynamic light scattering data (top) and TEM image (bottom) for glyconanoparticles (scale bar = 20 nm).

solvent mixture of  $\text{DMF}:\text{H}_2\text{O}$  (7:3). The resulting polymer was analyzed by SEC and possessed a number-average molecular weight ( $M_n$ ) of 14.2 kDa and a polydispersity index (PDI) of 1.16 (see Table 1). Next, the Tn-antigen glycan monomer **2** and poly(ethylene glycol) methyl ether methacrylate (PEGMA;  $M_n = 300$  Da) were copolymerized at varying comonomer feedstock ratios, with  $[\text{total monomer}]_0/[\text{CTA}]_0$  ratios of 100/1 and 50/1, and after 48 h all proceeded with excellent overall conversion (see Table 1). The number- and weight-average molecular weights ( $M_n$  and  $M_w$ ) determined by SEC were in good to excellent agreement with those predicted and the PDIs ranged from 1.12 to 1.23.

Sodium borohydride was then used to reduce simultaneously  $\text{HAuCl}_4$  to  $\text{Au}^0$  and the dithioester end groups of the RAFT polymers to thiol,<sup>18</sup> thereby forming a range of Tn-antigen glycan nanoparticles (polyTn-NPs) *in situ* (Figure 2 and Table 1). The polymer coronas of these particles varied in Tn glycan density (20, 50, and 100 mol %) and polymer  $\text{DP}_n$  (50 or 100 units). The size of the nanoparticles was confirmed by dynamic light scattering (DLS) and transmission electron microscopy

(TEM) (Figures 2, S1 and S2). All samples contained a narrow size distribution of particles of diameter between 5 and 20 nm, except for  $\text{PEG}_{40}\text{Tn}_{10}$  which resulted in a polydisperse sample (Figures S1 and S2). Determination of antigen and polymer loading using thermogravimetric analysis (TGA) indicated that not only could loading be tuned, but also that the use of longer polymer chains allowed the creation of smaller nanoparticles (Table 1, entries 4 and 5) with a lower mass fraction of gold core.

The Tn-antigen glycan presenting nanoparticles were analyzed for their efficacy and ability to induce an immune response *in vivo*. New Zealand White rabbits ( $n = 3$ ) were immunized at days 0, 14, 28, and 56 with either polyTn-NP or free polymer solution. Serum samples were taken at day 0 (preimmune bleed), 42 and 70 and antibodies present were quantified using an ELISA assay against the synthetic antigens. The results are presented in Figure 3a. The free polymers gave low or negligible response, whereas all glyconanoparticles generated a higher response that increased over time as judged by antibody (IgG) titers. Examination of the data in Figure 3a reveals a strong influence of nanoparticle composition on immunological properties. The highest titers were observed for AuNPs prepared with the polymers  $\text{PEG}_{25}\text{Tn}_{25}$  and  $\text{PEG}_{80}\text{Tn}_{20}$ , with weaker responses observed for  $\text{PEG}_{40}\text{Tn}_{10}$  and  $\text{PEG}_{50}\text{Tn}_{50}$  (subscript denotes number average block length). The polydispersity of  $\text{PEG}_{40}\text{Tn}_{10}$  may reduce its stability *in vivo* and hence produce lower titers than the other particles.

The relationship observed between carbohydrate density and immune response is notable. It appears that the optimum Tn-antigen glycan density is 20–25 units per polymer chain, regardless of chain length. Antigen induced cross-linking of B cell receptors leads to B cell activation and antibody production, whereas cross-linking with coreceptors can either increase or suppress B cell response.<sup>19</sup> It is likely that the glycoconjugate carbohydrate density has a strong influence on the subtle interplay between these factors and therefore on the production of antibodies.


Barchi et al. have prepared glycosylated gold nanoparticles bearing the Thomson-Friedenreich (TF) antigen and demonstrated moderate antibody responses.<sup>13b</sup> Direct comparison with their data is difficult since optical density values rather than serial dilution titers were reported; nonetheless, it seems that the maximum response of our nanoparticles is of the same order of magnitude.

To probe the ability of the nanoparticle-generated antibodies to recognize naturally occurring antigens, cross-reactivity with

**Table 1. Data for the Synthesis and Characterization of Glyconanoparticles**

polymer <sup>a</sup>	conv (%) <sup>b</sup>	yield (%)	$M_{n, \text{Tn}}$ (kDa) <sup>c</sup>	$M_n$ (kDa) <sup>d</sup>	PDI <sup>d</sup>	$D_h$ (nm) <sup>e</sup>	$F_{\text{Au}}$ (%) <sup>f</sup>	[Pol] (mmol) <sup>g</sup>	[Tn] (mmol) <sup>h</sup>
$\text{Tn}_{50}$	65	52	11.1	14.2	1.16	16	34	$4.7 \times 10^{-5}$	$2.3 \times 10^{-3}$
$\text{PEG}_{40}\text{Tn}_{10}$	99, 95 <sup>i</sup>	73	15.3	15.0	1.12	25	61	$4.1 \times 10^{-5}$	$2.0 \times 10^{-4}$
$\text{PEG}_{25}\text{Tn}_{25}$	90, 70 <sup>i</sup>	59	12.9	16.9	1.18	13	45	$3.3 \times 10^{-5}$	$2.0 \times 10^{-4}$
$\text{PEG}_{80}\text{Tn}_{20}$	99, 75 <sup>i</sup>	68	29.0	40.4	1.15	9	6	$2.3 \times 10^{-5}$	$3.0 \times 10^{-4}$
$\text{PEG}_{50}\text{Tn}_{50}$	99, 75 <sup>i</sup>	75	27.7	30.4	1.18	7	21	$2.6 \times 10^{-5}$	$1.0 \times 10^{-3}$

<sup>a</sup>PEG = poly(ethyleneglycol) methyl ether methacrylate, Tn = Tn-antigen glycan monomer **2**, subscript = target degree of polymerization. <sup>b</sup>Determined by  $^1\text{H}$  NMR spectroscopy by comparison of the integrals of the monomer alkene peaks to a selected polymer peak in the spectrum of the crude polymer. <sup>c</sup>Theoretical  $M_n$ , at observed conversion, determined from  $[\text{monomer}]_0/[\text{CTA}]_0$ . <sup>d</sup>Determined by SEC. <sup>e</sup>Mean hydrodynamic diameter determined by dynamic light scattering. <sup>f</sup>Mass fraction of Au per mg of nanoparticle, determined by thermogravimetric analysis. <sup>g</sup>Quantity of polymer per mg of nanoparticle, determined by thermogravimetric analysis. <sup>h</sup>Quantity of Tn-antigen glycan per mg of nanoparticle, determined by thermogravimetric analysis. <sup>i</sup>Values refer to copolymer first and second block, respectively.



**Figure 3.** Box plots showing results of immunological experiments with glyconanoparticles and glycopolymers. (a) Serum antibody (IgG) titers (ELISA); (b) cross-reactivity of serum antibodies (ELISA) with mucins. Tn = Tn-antigen glycan ( $\alpha$ -GalNAc), sTn = sialylated Tn; polymer key as in Table 1.

different mucin glycoproteins bearing the Tn-antigen was investigated. Bovine submaxillary mucin (BSM) is known to contain significant levels of sialylated Tn-residues (sTn),<sup>20</sup> which can be desialylated readily to expose Tn.<sup>21</sup> Serum samples (days 0 and 70) from immunization with glyconanoparticles presenting very different polymers PEG<sub>25</sub>Tn<sub>25</sub> and PEG<sub>80</sub>Tn<sub>20</sub> were reacted with mucins bearing Tn-antigen glycans in different forms (Figure 3b). While no or little detectable cross-reactivity was seen in day 0 samples, all experiments with 70 day samples indicated the presence of detectable levels of antibodies specific for naturally occurring mucin glycans. Interestingly, serum generated in the presence of each nanoparticle type showed the ability to bind the Tn-antigen glycan in both terminal and nonterminal context.

We have described the synthesis of 'multicopy-multivalent' nanoparticles decorated with tumor-associated (Tn) antigen glycans and have shown that these generate a significant immune response *in vivo*, with promising indications that the antibodies generated are capable of recognizing natural Tn-antigen glycans and mammalian-mucin glycoproteins. While the absolute titers reported here are lower than those obtained with glycoconjugates based on protein toxin platforms,<sup>22</sup> the ability to create fully synthetic protein- and peptide-free glycoconjugate vaccines through layered multivalent display is the first of its kind.

## ■ ASSOCIATED CONTENT

### Ⓢ Supporting Information

Procedures for glycomonomer, glycopolymer and nanoparticle preparation, immunization experiments and characterization

data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

n.r.cameron@durham.ac.uk; ben.davis@chem.ox.ac.uk

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

The authors thank the MRC and EPSRC (joint grant reference G0700080) for funding. N.R.C. acknowledges the P2M RNP programme of the European Science Foundation. B.G.D. is a recipient of a Royal Society Wolfson Merit Award. Professor Quentin Sattentau (Sir William Dunn School of Pathology, University of Oxford) is thanked for helpful discussions.

## ■ REFERENCES

- (1) (a) Picco, G.; Julien, S.; Brockhausen, I.; Beatson, R.; Antonopoulos, A.; Haslam, S.; Mandel, U.; Dell, A.; Pinder, S.; Taylor-Papadimitriou, J.; Burchell, J. *Glycobiology* **2010**, *20*, 1241. (b) Beatson, R. E.; Taylor-Papadimitriou, J.; Burchell, J. M. *Immunotherapy* **2010**, *2*, 305.
- (2) (a) Danishefsky, S. J.; Allen, J. R. *Angew. Chem., Int. Ed.* **2000**, *39*, 836. (b) Buskas, T.; Thompson, P.; Boons, G. J. *Chem. Commun.* **2009**, 5335. (c) Guo, Z. W.; Wang, Q. L. *Curr. Opin. Chem. Biol.* **2009**, *13*, 608.
- (3) (a) Jeon, I.; Lee, D.; Krauss, I. J.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2009**, *131*, 14337. (b) Ragupathi, G.; Koide, F.; Livingston, P. O.; Cho, Y. S.; Endo, A.; Wan, Q.; Spassova, M. K.; Keding, S. J.; Allen, J.; Ouerfelli, O.; Wilson, R. M.; Danishefsky, S. J. *J. Am. Chem. Soc.* **2006**, *128*, 2715. (c) Westerlind, U.; Hobel, A.; Gaidzik, N.; Schmitt, E.; Kunz, H. *Angew. Chem., Int. Ed.* **2008**, *47*, 7551.
- (4) (a) Buskas, T.; Ingale, S.; Boons, G. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 5985. (b) Kaiser, A.; Gaidzik, N.; Becker, T.; Menge, C.; Groh, K.; Cai, H.; Li, Y. M.; Gerlitzki, B.; Schmitt, E.; Kunz, H. *Angew. Chem., Int. Ed.* **2010**, *49*, 3688. (c) Cai, H.; Huang, Z. H.; Shi, L.; Zhao, Y. F.; Kunz, H.; Li, Y. M. *Chem.—Eur. J.* **2011**, *17*, 6396. (d) Ingale, S.; Awolfert, M.; Gaekwad, J.; Buskas, T.; Boons, G. J. *Nat. Chem. Biol.* **2007**, *3*, 663.
- (5) Keil, S.; Kaiser, A.; Syed, F.; Kunz, H. *Synthesis* **2009**, 1355.
- (6) Wittrock, S.; Becker, T.; Kunz, H. *Angew. Chem., Int. Ed.* **2007**, *46*, 5226.
- (7) (a) Slovin, S. F.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kim, S.; Spassova, M.; Bornmann, W. G.; Fazzari, M.; Dantis, L.; Olkiewicz, K.; Lloyd, K. O.; Livingston, P. O.; Danishefsky, S. J.; Scher, H. I. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 5710. (b) Gilewski, T.; Ragupathi, G.; Bhuta, S.; Williams, L. J.; Musselli, C.; Zhang, X. F.; Bencsath, K. P.; Panageas, K. S.; Chin, J.; Hudis, C. A.; Norton, L.; Houghton, A. N.; Livingston, P. O.; Danishefsky, S. J. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 3270. (c) Krug, L. M.; Ragupathi, G.; Hood, C.; Kris, M. G.; Miller, V. A.; Allen, J. R.; Keding, S. J.; Danishefsky, S. J.; Gomez, J.; Tyson, L.; Pizzo, B.; Baez, V.; Livingston, P. O. *Clin. Cancer Res.* **2004**, *10*, 6094. (d) Sabbatini, P. J.; Kudryashov, V.; Ragupathi, G.; Danishefsky, S. J.; Livingston, P. O.; Bornmann, W.; Spassova, M.; Zatorski, A.; Spriggs, D.; Aghajanian, C.; Soignet, S.; Peyton, M.; O'Flaherty, C.; Curtin, J.; Lloyd, K. O. *Int. J. Cancer* **2000**, *87*, 79. (e) Slovin, S. F.; Ragupathi, G.; Musselli, C.; Fernandez, C.; Diani, M.; Verbel, D.; Danishefsky, S.; Livingston, P.; Scher, H. I. *Cancer Immunol. Immunother.* **2005**, *54*, 694. (f) Sabbatini, P. J.; Ragupathi, G.; Hood, C.; Aghajanian, C. A.; Juertzka, M.; Lasonos, A.; Hensley, M. L.; Spassova, M. K.; Ouerfelli, O.; Spriggs, D. R.; Tew, W. P.; Konner, J.; Clausen, H.; Abu Rustum, N.; Danishefsky, S. J.; Livingston, P. O. *Clin. Cancer Res.* **2007**, *13*, 4170.
- (8) (a) Hong, S. Y.; Tobias, G.; Al-Jamal, K. T.; Ballesteros, B.; Ali-Boucetta, H.; Lozano-Perez, S.; Nellist, P. D.; Sim, R. B.; Finucane, C.; Mather, S. J.; Green, M. L. H.; Kostarelos, K.; Davis, B. G. *Nat. Mater.*

2010, 9, 485. (b) van Kasteren, S. I.; Campbell, S. J.; Serres, S.; Anthony, D. C.; Sibson, N. R.; Davis, B. G. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 18.

(9) (a) Barrientos, A. G.; de la Fuente, J. M.; Rojas, T. C.; Fernandez, A.; Penades, S. *Chem.—Eur. J.* **2003**, *9*, 1909. (b) Garcia, I.; Marradi, M.; Penades, S. *Nanomedicine* **2010**, *5*, 777. (c) De la Fuente, J. M.; Penades, S. *Biochim. Biophys. Acta* **2006**, *1760*, 636. (d) Sundgren, A.; Barchi, J. J. *Carbohydr. Res.* **2008**, *343*, 1594. (e) Svarovsky, S. A.; Szekely, Z.; Barchi, J. J. *Tetrahedron: Asymmetry* **2005**, *16*, 587.

(10) (a) de la Fuente, J. M.; Barrientos, A. G.; Rojas, T. C.; Rojo, J.; Canada, J.; Fernandez, A.; Penades, S. *Angew. Chem., Int. Ed.* **2001**, *40*, 2258. (b) Hernaiz, M. J.; de la Fuente, J. M.; Barrientos, A. G.; Penades, S. *Angew. Chem., Int. Ed.* **2002**, *41*, 1554. (c) de la Fuente, J. M.; Eaton, P.; Barrientos, A. G.; Menendez, M.; Penades, S. *J. Am. Chem. Soc.* **2005**, *127*, 6192.

(11) Rojo, J.; Diaz, V.; de la Fuente, J. M.; Segura, I.; Barrientos, A. G.; Riese, H. H.; Bernade, A.; Penades, S. *ChemBioChem* **2004**, *5*, 291.

(12) Marradi, M.; Di Gianvincenzo, P.; Enriquez-Navas, P. M.; Martinez-Avila, O. M.; Chiodo, F.; Yuste, E.; Angulo, J.; Penades, S. *J. Mol. Biol.* **2011**, *410*, 798.

(13) (a) Ojeda, R.; de Paz, J. L.; Barrientos, A. G.; Martin-Lomas, M.; Penades, S. *Carbohydr. Res.* **2007**, *342*, 448. (b) Brinas, R. P.; Sundgren, A.; Sahoo, P.; Morey, S.; Rittenhouse-Olson, K.; Wilding, G. E.; Deng, W.; Barchi, J. J. *Bioconjugate Chem.* **2012**, *23*, 1513.

(14) (a) Spain, S. G.; Cameron, N. R. *Polym. Chem.* **2011**, *2*, 60. (b) Ting, S. R. S.; Chen, G. J.; Stenzel, M. H. *Polym. Chem.* **2010**, *1*, 1392. (c) Spain, S. G.; Gibson, M. I.; Cameron, N. R. *J. Polym. Sci., Part A: Polym. Chem.* **2007**, *45*, 2059. (d) Admiral, V.; Melia, E.; Haddleton, D. M. *Eur. Polym. J.* **2004**, *40*, 431.

(15) Kuduk, S. D.; Schwarz, J. B.; Chen, X. T.; Glunz, P. W.; Sames, D.; Ragupathi, G.; Livingston, P. O.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1998**, *120*, 12474.

(16) O'Neil, I. A.; Thompson, S.; Murray, C. L.; Barret Kalindjian, B. *Tetrahedron Lett.* **1998**, *39*, 7787.

(17) (a) Chieffari, J.; Chong, Y. K.; Ercole, F.; Krstina, J.; Jeffery, J.; Le, T. P. T.; Mayadunne, R. T. A.; Meijs, G. F.; Moad, C. L.; Moad, G.; Rizzardo, E.; Thang, S. H. *Macromolecules* **1998**, *31*, 5559. (b) Moad, G.; Rizzardo, E.; Thang, S. H. *Acc. Chem. Res.* **2008**, *41*, 1133. (c) Moad, G.; Rizzardo, E.; Thang, S. H. *Polymer* **2008**, *49*, 1079.

(18) (a) Lowe, A. B.; Sumerlin, B. S.; Donovan, M. S.; McCormick, C. L. *J. Am. Chem. Soc.* **2002**, *124*, 11562. (b) Raula, J.; Shan, J.; Nuopponen, M.; Niskanen, A.; Jiang, H.; Kauppinen, E. I.; Tenhu, H. *Langmuir* **2003**, *19*, 3499. (c) Shan, J.; Nuopponen, M.; Jiang, H.; Viitala, T.; Kauppinen, E.; Kontturi, K.; Tenhu, H. *Macromolecules* **2005**, *38*, 2918.

(19) (a) Kurosaki, T. *Curr. Opin. Immunol.* **2002**, *14*, 341. (b) Dal Porto, J. M.; Gauld, S. B.; Merrell, K. T.; Mills, D.; Pugh-Bernard, A. E.; Cambier, J. *Mol. Immunol.* **2004**, *41*, 599.

(20) Yu, G.-L.; Zhang, Y.-B.; Zhang, Z.-Q.; Song, L.-T.; Wang, P.-P.; Chai, W.-A. *Anal. Chem.* **2010**, *82*, 9534.

(21) O'Boyle, K. P.; Coatsworth, S.; Anthony, G.; Ramirez, M.; Greenwald, E.; Kaley, R.; Steinberg, J. J.; Dutcher, J. P.; Wiernik, P. H. *Cancer Immun.* **2006**, *6*, 5.

(22) Hoffmann-Roder, A.; Kaiser, A.; Wagner, S.; Gaidzik, N.; Kowalczyk, D.; Westerlind, U.; Gerlitzki, B.; Schmitt, E.; Kunz, H. *Angew. Chem., Int. Ed.* **2010**, *49*, 8498.